Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma.

ABSTRACT:

Background

Functional profiling of freshly isolated glioblastoma (GBM) cells is being evaluated as a next-generation method for precision oncology. While promising, its success largely depends on the method to evaluate treatment activity which requires sufficient resolution and specificity.

Methods

Here, we describe the 'precision oncology by single-cell profiling using ex vivo readouts of functionality' (PROSPERO) assay to evaluate the intrinsic susceptibility of high-grade brain tumor cells to respond to therapy. Different from other assays, PROSPERO extends beyond life/death screening by rapidly evaluating acute molecular drug responses at single-cell resolution.

Results

The PROSPERO assay was developed by correlating short-term single-cell molecular signatures usi

SUBMITTER: Panovska D 

PROVIDER: S-EPMC11071868 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature